AstraZeneca has decided to cut its losses and drop the Phase III antidepressant candidate TC-5214 that it licensed from Targacept in December 2009.
AstraZeneca has decided to cut its losses and drop the Phase III antidepressant candidate TC-5214 that it licensed from Targacept in December 2009.
It said that it would not pursue a regulatory filing for the novel neuronal nicotinic receptor antagonist after reporting that...
Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.
The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.
Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.
MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.
